Clinical Trial

Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus Erythematosus

Study acronym: CARLYSLE
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1 study of obecabtagene autoleucel (obe-cel), autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19, to establish the tolerability, safety, preliminary efficacy, and pharmacokinetics of obe-cel in patients with severe, refractory SLE.
Protocol Amendment History 2 changes
critical Enrollment closed, study ongoing 2026-08-01
notable Enrollment reduced: 18 -> 16 participants 2026-08-01
Trial Details
NCT Number NCT06333483
Lead Sponsor Autolus Limited
Conditions Systemic Lupus Erythematosus
Enrollment 16 participants
Start Date 2024-02-02
Primary Completion 2027-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-31